February 9, 2011 9:38 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Goldman Sachs is out with a research report this morning, where its analysts suggest that traders buy calls on Vertex Pharmaceuticals (NASDAQ: VRTX) ahead of several catalysts.The analysts expect shares to be especially volatile around seven upcoming catalysts, most relating to TVR (Telaprevir), a new drug for HCV (hepatitis C infection) which could represent over 80% of VRTX sales by next year. TVR is at the leading edge of a paradigm shift for the treatment of HCV, a market that is expected to grow to $10-$12bn from $3bn following the introduction of new oral drugs, with improved cure rates and shorter treatment durations. They suggest buying the July $41.00 call for $3.50. Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.